ArticleTherapeutic innovation & regulatory science2026
Patient-Reported Outcomes Used for Regulatory Approval of Medicines Indicated for the Treatment of Dermatological Diseases Authorized in the European Union Between 1998 and 2024.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient-reported outcomes (PROs) have gained increasing relevance in medicine approvals, particularly in dermatology, where traditional clinical and laboratory endpoints may not fully capture the patient's experience or treatment impact. This study aimed to assess the use of PROs in the European Commission's (EC) marketing authorizations for medicines indicated for dermatological diseases between 1998 and 2024.
methodsThe European Public Assessment Reports (EPARs) and Summary of Product Characteristics (SmPCs) of approved medicines indicated for dermatological diseases approved between 1998 and 2024 were reviewed. For medicines including PROs, detailed information regarding their characteristics, applications and PRO label claims was collected.
resultsOf the 21 medicines approved by the EC between 1998 and 2024, 14 (66.7%) incorporated PROs, and 9 (64.3%) of those received a PRO label claim. Across the 64 studies included in the EPARs, 45 distinct PRO Measures (PROMs) were identified. The most common purpose of PROMs was to capture signs/symptoms (n = 15; 33.3%). PRO use was identified in 314 instances, of which 114 (36.3%) were categorized as PRO-related secondary endpoints. Five (35.7%) medicines were not granted PRO label claims due to a lack of benefit, missing data, limited PROM validation, small sample size, or study design issues.
conclusionsPRO use in dermatology regulatory submissions is evident and plays a valuable role in conveying the patient perspective. Overcoming operational and methodological challenges, ensuring stakeholder alignment, and striking a balance between instrument diversity and utility could strengthen the integration of PROs into patient-centric regulatory decision-making.
Indexed as
Identifiers
42611415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.